Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Teva
Mallinckrodt
Chinese Patent Office
McKinsey
Johnson and Johnson
Federal Trade Commission
US Army
Healthtrust

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021162

« Back to Dashboard

NDA 021162 describes MICARDIS HCT, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the MICARDIS HCT profile page.

The generic ingredient in MICARDIS HCT is hydrochlorothiazide; telmisartan. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.
Summary for 021162
Tradename:MICARDIS HCT
Applicant:Boehringer Ingelheim
Ingredient:hydrochlorothiazide; telmisartan
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021162
Ingredient-typeThiazides
Mechanism of ActionAngiotensin 2 Receptor Antagonists
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 021162
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162 NDA AUTHORIZED GENERIC West-Ward Pharmaceuticals Corp. 0054-0545 N 0054-0545-18
MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162 NDA AUTHORIZED GENERIC West-Ward Pharmaceuticals Corp. 0054-0546 N 0054-0546-18

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;40MG
Approval Date:Nov 17, 2000TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 10, 2020Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;80MG
Approval Date:Nov 17, 2000TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 10, 2020Product Flag?Substance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;80MG
Approval Date:Apr 19, 2004TE:ABRLD:Yes

Expired US Patents for NDA 021162

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-003 Apr 19, 2004 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-001 Nov 17, 2000 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-002 Nov 17, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Healthtrust
US Department of Justice
Medtronic
Cantor Fitzgerald
Daiichi Sankyo
Argus Health
Cerilliant
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.